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Background: Exogenous use of the intestinal hormone glucagon-like peptide 1 (GLP-1) lowers glycaemia
by stimulation of insulin, inhibition of glucagon, and delay of gastric emptying.
Aims: To assess the effects of endogenous GLP-1 on endocrine pancreatic secretion and antro-pyloro-
duodenal motility by utilising the GLP-1 receptor antagonist exendin(9-39)amide (ex(9-39)NH2).
Methods: Nine healthy volunteers underwent four experiments each. In two experiments with and without
intravenous infusion of ex(9-39)NH2 300 pmol/kg/min, a fasting period was followed by intraduodenal
glucose perfusion at 1 and 2.5 kcal/min, with the higher dose stimulating GLP-1 release. Antro-pyloro-
duodenal motility was measured by perfusion manometry. To calculate the incretin effect (that is, the
proportion of plasma insulin stimulated by intestinal hormones) the glycaemia observed during the luminal
glucose experiments was mimicked using intravenous glucose in two further experiments.
Results: Ex(9-39)NH2 significantly increased glycaemia during fasting and duodenal glucose. It
diminished plasma insulin during duodenal glucose and significantly reduced the incretin effect by
approximately 50%. Ex(9-39)NH2 raised plasma glucagon during fasting and abolished the decrease in
glucagon at the high duodenal glucose load. Ex(9-39)NH2 markedly stimulated antroduodenal
contractility. At low duodenal glucose it reduced the stimulation of tonic and phasic pyloric motility. At
the high duodenal glucose load it abolished pyloric stimulation.
Conclusions: Endogenous GLP-1 stimulates postprandial insulin release. The pancreatic a cell is under the
tonic inhibitory control of GLP-1 thereby suppressing postprandial glucagon. GLP-1 tonically inhibits
antroduodenal motility and mediates the postprandial inhibition of antral and stimulation of pyloric
motility. We therefore suggest GLP-1 as a true incretin hormone and enterogastrone in humans.
G
lucagon-like peptide-1(7–36)amide (GLP-1) is a gut
born hormone released from L cells in response to
nutrients and, especially, carbohydrates. GLP-1 has
been shown in vitro and in vivo to reduce glucagon and to
stimulate insulin secretion.1–4 A dominant gastrointestinal
action of synthetic GLP-1 is inhibition of gastroduodenal and
stimulation of pyloric motility,5 6 resulting in a delay in
gastric emptying and decreased glycaemic excursions.3 4 7–9
These combined effects improve glucose tolerance providing
the rationale for the therapeutic potential of GLP-1 analogues
in the treatment of diabetes mellitus.
Most of our understanding of the effects of GLP-1 on
postprandial glucose homoeostasis is based on studies using
synthetic GLP-1 whereas little is known of endogenously
released GLP-1. The availability of a powerful GLP-1 receptor
antagonist exendin(9-39)amide (ex(9-39)NH2) allows us to
evaluate whether GLP-1 acts as an incretin hormone and/or
enterogastrone in humans. The usefulness of the antagonist
became evident in initial studies demonstrating that endo-
genously released peptide enhances postprandial insulin
release in rats.10 11 With this antagonist introduced in
humans, evidence was found that the pancreatic a cell is
under tonic inhibitory control by fasting levels of GLP-1.12
Blockade of GLP-1 by ex(9-39)NH2 after an oral glucose meal
resulted in a 35% increase in postprandial glucose excur-
sions.13
To date, the exact role of GLP-1 in the regulation and
interplay of the endocrine pancreas and gastroduodenal
motility is unclear. To shed more light onto this important
issue, we used the GLP-1 antagonist to define the physiolo-
gical actions of endogenously released GLP-1 on the pancreas
and upper gastrointestinal motility in humans. We stimu-
lated GLP-1 release by graded duodenal glucose perfusion,
utilising caloric loads below and above the threshold for
GLP-1 release.14 We avoided the gastric route of glucose
entering the intestine, excluding interferences caused by
putatively accelerated gastric emptying in response to ex(9-
39)NH2.
MATERIAL AND METHODS
Subjects
Nine healthy male volunteers, 22–28 years of age, body mass
index 22–24 kg/m2, participated in the studies. None was
taking any medication, and all were free of gastrointestinal
symptoms or any systemic disease. The studies were
approved by the local ethics committee and all participants
provided written informed consent.
Experimental protocol
All experiments were performed in a double blind fashion on
different days after an overnight fast. Experiments in
respective individuals were separated by at least seven days
(range 7–78 days). Each subject underwent two series of two
experiments each in random order. In the first series,
volunteers swallowed a nine lumen duodenal sleeve/side
hole catheter with its tip positioned at the ligament of Treitz.
The catheter was used for continuous recording of antro-
pyloro-duodenal motility and for duodenal perfusion of
Abbreviations: ex(9-39)NH2, exendin(9-39)amide; GLP-1, glucagon-
like peptide 1; GIP, glucose dependent insulinotropic polypeptide; IPPW,
isolated pyloric pressure waves; SR, secretory response
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glucose solution. An interdigestive period of 60 minutes was
followed by intraduodenal glucose perfusion (1 kcal/ml) at
1 kcal/minute for 60 minutes and at 2.5 kcal/minute for
another 120 minutes. These glucose loads are below and
above the threshold for GLP-1 release, respectively.14 Starting
30 minutes before duodenal glucose perfusion in the fasting
state, ex(9-39)NH2 300 pmol/kg/min
12 or saline was infused
intravenously. During the last 60 minutes of the experiments,
saline was infused instead of ex(9-39)NH2 to allow for
recovery of effects.
In the second series, two further experiments without
duodenal intubation were performed in each subject to
calculate the incretin effect (that is, proportion of total
postprandial insulin secretion stimulated by intestinal
hormones). The incretin effect was quantified by comparing
insulin and C peptide responses during the duodenal glucose
load and during isoglycaemic intravenous glucose infusion.
The time course of blood glucose during the duodenal glucose
load both with and without intravenous ex(9-39)NH2 was
mimicked by intravenous glucose. Glucose 20% was intrave-
nously infused, and infusion rate adjustments were per-
formed according to a modified method of DeFronzo and
colleagues15 based on five minute blood glucose determina-
tions. Isoglycaemic intravenous glucose infusions provide a
measure of b cell secretory responses to the glycaemic
stimulus without superimposed incretin effects. The differ-
ence in incremental b cell secretory responses (SR) to both of
these stimuli represents the action of incretin factors and is
expressed as the percentage of the physiological response to
duodenal glucose, which is taken as the denominator
(100%)16:
Incretin effect = (SRduodenal 2 SRisoglycaemic iv) / SRduodenal
6 100%
Samples of arterialised blood (‘‘heated hand’’12) were taken
at 10 minute intervals throughout each experiment. Blood
was collected in ice chilled EDTA tubes containing aprotinin
1000 kallikrein inhibitory units/ml blood and centrifuged
immediately. Plasma was stored at 220 C˚ until assayed.
Motil ity recording
Perfusion manometry was recorded using a nine lumen
duodenal sleeve/side hole catheter (Dentsleeve, South
Australia, Australia). The manometric assembly incorporated
a 4.5 cm sleeve sensor, two antral side holes (2 cm apart),
and three duodenal side holes (2 cm apart), beginning at the
proximal and distal ends of the sleeve, respectively. Two
further side holes were positioned along the sleeve spaced
1.5 cm apart. An additional lumen located 12 cm distal to the
sleeve sensor was used for duodenal perfusion.
The position of the catheter with the sleeve array straddling
the pylorus was monitored by measuring the transmucosal
potential difference between the distal antral and proximal
duodenal port.14 A difference of at least 215 mV indicated
the correct transpyloric position of the tube.
Motility channels were perfused at a rate of 0.3 ml/min
using a low compliance pneumohydraulic pump (Arndorfer
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Figure 1 Effects of intravenous exendin(9-39)NH2 300 pmol/kg/min on plasma immunoreactivities of glucagon-like peptide 1(GLP-1) (A) and
glucose dependent insulinotropic polypeptide (GIP) (B) during fasting and with duodenal glucose perfusion of 1 and 2.5 kcal/min in nine healthy
volunteers. Intravenous infusions were discontinued after 150 minutes. For statistical analysis, see table 1.
Table 1 Effect of duodenal glucose perfusion on blood glucose and plasma immunoreactivities of gastrointestinal peptides
with and without intravenous exendin(9-39)NH2
Intravenous infusion
Duodenal glucose perfusion rate (60 min each)
1 kcal/min 2.5 kcal/min 2.5 kcal/min (recovery)
Saline iv Ex(9-39) Saline iv Ex(9-39) Saline iv Saline iv
GLP-1 (pmol/l/60 min) 20.5 (1.3) 20.4 (1.5) 13 (4.5) 29 (7.4)* 25 (5.5) 30 (10)
GIP (pg/ml/60 min) 247 (52) 337 (90) 801 (116) 904 (121) 1319 (166) 1151 (93)
Blood glucose (mmol/l/60 min) 6.4 (0.5) 8.3 (0.9)* 13 (1.1) 18 (1.6)* 7.4 (1.0) 9.2 (1.3)
Insulin (mU/l/60 min) 62 (8.3) 54 (9.5) 287 (40) 220 (38)* 194 (27) 195 (35)
C-peptide (ng/ml/60 min) 9.1 (0.7) 7.6 (0.8) 34 (5.8) 28 (4.9) 31 (5.0) 33 (6.7)
Glucagon (pg/ml/60 min) 280 (11) 15 (16)* 2138 (25) 5.4 (23)* 2156 (31) 246 (25)*
iv, intravenous; GLP-1, glucagon-like peptide 1; GIP, glucose dependent insulinotropic polypeptide.
Mean (SEM) of AUC over basal during each 60 minute perfusion period (n = 9). Differences were compared using two way repeated measures ANOVA
employing individual incremental or decremental values over basal during the respective periods.
*p,0.05 versus saline iv.
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Medical Specialists, Greendale, Wisconsin, USA). Data were
sampled at 8 Hz on a multichannel chart system (Medical
Measurement Systems, Enschede, the Netherlands).
Analysis of motil ity tracings
Analysis of contractile events was performed as previously
described.6 17 Only peaks with amplitudes of at least
10 mm Hg and durations of at least two seconds were
considered true pressure waves. Antral phase III was defined
as the occurrence of regular pressure waves at a frequency
>3/minute for at least two minutes in the antrum,
propagated aborally. Data were analysed in 10 minute
intervals separately for the antrum and duodenum by
summarising (frequency, motility index) or averaging
(amplitude) the values derived from the antral and duodenal
side holes, respectively. Motility indices were determined as
area under the pressure waves and expressed as mm Hg6s/
min.
Isolated pyloric pressure waves (IPPW) were defined as
pressure waves registered by the sleeve with simultaneous
pressure waves maximally in one sleeve-side hole in the
absence of associated (¡3 seconds) waves in the adjacent
antral and duodenal side holes. Pyloric tone was measured as
the difference in basal pressures recorded by the sleeve and
by the antral side hole at the proximal end of the sleeve.18
Basal pressures (that is, mean pressures after excluding
pressure waves) were obtained for each minute and were
used to calculate mean pyloric tone.
Exendin(9-39)amide
Synthetic ex(9-39)NH2 was purchased from PolyPeptide
Laboratories (Wolfenbu¨ttel, Germany). Peptide content
amounted to 90.6% with a peptide purity .98%. High
performance liquid chromatography showed a single peak
for ex(9-39)NH2. The peptide was dissolved in 1% human
serum albumin, filtered through 0.2 mm nitrocellulose filters,
and stored at 270 C˚. Samples were tested for pyrogens and
bacterial growth and no contamination with bacterials or
endotoxins was detected.
Determinations and assays
Blood glucose concentrations were measured by the glucose
oxidase method (YSI 1500G; Schlag, Bergisch-Gladbach,
Germany). Plasma insulin was measured by the Abbott
Imx Microparticle Enzyme Immunoassay, with an average
intra-assay coefficient of variation of 5%. Immunoreactivities
of C peptide, glucagon, and glucose dependent insulino-
tropic polypeptide (GIP) were analysed by commercially
9
8
7
6
5
4
0–30 30 60 90 120 150 180 210
Time (minutes)
0–30 30 60 90 120 150 180 210
Time (minutes)
0–30 30 60 90 120 150 180 210
Time (minutes)
0 30 60 90 120 150 180 210
Time (minutes)
Bl
oo
d 
gl
uc
os
e 
(m
m
ol
/l
)
80
60
40
20
0
In
su
lin
 (m
U
/l
)
70
60
50
40
30
20
10
0
In
cr
em
en
ta
l i
ns
ul
in
 (m
U
/l
)
9
6
7
8
5
4
3
2
1
0
In
cr
em
en
ta
l C
-p
ep
tid
e 
(n
g/
m
l)
1 kcal/min 1 kcal/min2.5 kcal/min 2.5 kcal/min
Duodenal glucose Duodenal glucose
1 kcal/min1 kcal/min 2.5 kcal/min2.5 kcal/min
Duodenal glucoseDuodenal glucose
C  Incretin effect: insulin D  Incretin effect: C-peptide
A  Glucose B  Insulin
Exendin(9-39)NH2
Saline
Exendin(9-39)NH2
Saline
p<0.05 for saline
v ex(9-39)NH2
Isoglycaemic glucose
Total postprandial
C-peptide (saline iv)
Saline iv
Exendin(9-39)NH2
incretin effect with
Total postprandial
insulin (saline iv)
Saline iv
Exendin(9-39)NH2
incretin effect with
Figure 2 Effects of intravenous exendin(9-39)NH2 300 pmol/kg/min on blood glucose (A) and plasma immunoreactivity of insulin (B) during fasting
and with duodenal glucose perfusion of 1 and 2.5 kcal/min in nine healthy volunteers. Intravenous infusions were discontinued after 150 minutes.
Square symbols represent data during isoglycaemic intravenous glucose, mimicking blood glucose levels of the two experiments with saline and
exendin(9-39)NH2 to calculate the incretin effect (C, D). The incretin effect was calculated as the difference in incremental insulin (C) and C peptide (D)
plasma levels between duodenal glucose perfusion and the respective isoglycaemic clamp experiment. For statistical analysis, see tables 1 and 2.
GLP-1 and antro-pyloro-duodenal motility 245
www.gutjnl.com
 group.bmj.com on April 25, 2013 - Published by gut.bmj.comDownloaded from 
available radioimmunoassay kits (Biermann, Bad Nauheim,
Germany). Immunoreactivity of GLP-1 was measured using
the specific polyclonal antibody GA1178 (Affinity Research,
Nottingham, UK).14 Immunoreactivities of GLP-1 were
extracted from plasma samples on C-18 cartridges using
acetonitrile for elution of samples. The antiserum did
not cross react with ex(9-39)NH2, GIP, pancreatic glucagon,
glicentin, oxyntomodulin, or GLP-2. The detection limit of
the assay was 0.25 pmol/l. Intra- and inter-assay coefficients
of variation were 3.6% and 10.7%, respectively.
Statistical analysis
Power calculations were performed based on a two tailed
paired t test at the 5% significance level. With respect to the
incretin effect, a sample size of nine subjects ensured a power
of 86% to yield a statistically significant difference of at least
20%. This calculation was based on an intersubject coefficient
of variation of 0.27.19 With respect to pyloric tone, a sample
size of nine subjects ensured a power of 94% to yield a
statistically significant difference of at least 2 mm Hg. This
calculation was based on an intersubject coefficient of
variation of 0.47 derived from experiments with duodenal
lipid perfusion.6
All values are expressed as mean (SEM). Parameters were
separately analysed for the first 30 minute period during the
fasting state and for each 60 minute period of duodenal
glucose perfusion. Pyloric tone was calculated as change from
basal, the latter being determined as mean pyloric tone
during the basal period before starting the intravenous
infusions. Differences in plasma hormones and glucose
compared with the basal state were calculated as integrated
values over basal (area under the response curve; AUC). Basal
levels were determined as the mean of two basal values just
before the start of each experiment. All samples were first
tested for normality by the Komolgoroff-Smirnoff test.
Differences between experimental sets for each parameter
were analysed by two way repeated measures ANOVA using
intravenous infusion and duodenal perfusion as factors. With
respect to each parameter analysed, ANOVA did not indicate
a significant interaction between intravenous infusion and
rate of intraduodenal glucose. Thus the effect of intravenous
infusion did not depend on what level of glucose perfusion
was present. When ANOVA indicated differences, a Student-
Newman-Keuls multicomparison test was performed.
Differences were considered significant at p,0.05.
RESULTS
Plasma immunoreactivities of gastrointestinal
peptides and blood glucose
Duodenal glucose perfusion
GLP-1 plasma levels did not increase during perfusion of
duodenal glucose at 1 kcal/min, in contrast with 2.5 kcal/min
which elicited an increase in GLP-1 (fig 1 A). Compared with
saline, ex(9-39)NH2 did not influence GLP-1 plasma levels
during the fasting state or with low duodenal glucose but
approximately doubled plasma GLP-1 during the high
duodenal glucose load (fig 1A, table 1).
Even during fasting, ex(9-39)NH2 significantly increased
blood glucose (4.9 (0.16) v 4.4 (0.07); p,0.05 v saline
control) (fig 2A). This was accompanied by a significant
increase in basal plasma glucagon levels (fig 3) but not
plasma insulin (fig 2B).
Duodenal glucose perfusion dose dependently enhanced
blood glucose levels (fig 2A). This was paralleled by an
increase in plasma insulin and a decrease in plasma glucagon
(figs 2B, 3). Compared with saline, ex(9-39)NH2 significantly
increased blood glucose, during both the low and high
duodenal glucose perfusion, by 29% and 31%, respectively
(fig 2, table 1). Plasma insulin significantly decreased with
ex(9-39)NH2 during high duodenal glucose but remained
unchanged during the low duodenal glucose load. After
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Figure 3 Effects of intravenous exendin(9-39)NH2 300 pmol/kg/min
on plasma immunoreactivities of glucagon during fasting and with
duodenal glucose perfusion of 1 and 2.5 kcal/min in nine healthy
volunteers. Intravenous infusions were discontinued after 150 min.
Square symbols indicate data for plasma glucagon during isoglycaemic
glucose clamps, mimicking blood glucose levels in the two experi-
ments with saline and exendin(9-39)NH2 For statistical analysis, see
table 1.
Table 2 Isoglycaemic clamp studies mimicking glycaemia. Blood glucose and b cell response during intravenous glucose
infusion.
Saline iv Ex(9-39) iv
Duodenal glucose (kcal/min) 1 2.5 2.5 (recovery) 1 2.5 2.5 (recovery)
Blood glucose (mmol/l/60 min) 7.0 (0.6) 13 (1.3) 7.6 (0.8) 8.7 (0.8)* 17 (1.4)* 8.6 (1.2)
Intravenous glucose load (kcal) 54 (2.9) 98 (10) 75 (10) 59 (5.8) 106 (16) 95 (17)
Insulin (mU/l/60 min) 31 (7.3) 84 (18) 43 (8.8) 40 (8.6) 118 (30)* 77 (24)*
C peptide (ng/ml/60 min) 5.2 (0.7) 15 (2.8) 13 (1.8) 5.8 (1.0) 20 (4.9)* 21 (7.4)*
Incretin effect based on insulin (%) 48 (8.2) 70 (5.6) 76 (4.4) 23 (6.0)* 36 (5.2)* 58 (3.9)*
Incretin effect based on C peptide (%) 41 (8.5) 51 (9.1) 54 (8.8) 19 (11)* 22 (11)* 36 (11)*
Ex(9-39), exendin(9-39)amide; iv, intravenous.
Mean (SEM) of AUC over basal during each 60 minute infusion period (n = 9). The incretin effect reflects the difference in incremental b cell secretory response
between duodenal glucose, as shown in table 1, and isoglycaemic intravenous glucose shown here. Differences were compared using two way repeated measures
ANOVA employing individual incremental or decremental values over basal during the respective periods.
*p,0.05 versus experiments mimicking glycaemia during duodenal glucose and saline iv.
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cessation of ex(9-39)NH2, blood glucose and plasma insulin
levels reached those obtained with saline.
During duodenal perfusion of glucose, plasma glucagon
levels steadily decreased throughout the experiments (fig 3).
This effect was completely abolished by ex(9-39)NH2.
However, accounting for the effects on fasting levels of
glucagon, ex(9-39)NH2 did not change the glucagon response
to duodenal glucose at 1 kcal/min. The further decrease in
plasma glucagon with duodenal glucose at 2.5 kcal/min,
however, was completely blocked by ex(9-39)NH2. This was
reversible after cessation of ex(9-39)NH2. Endogenous GLP-1
not only tonically suppressed fasting glucagon but further
inhibited postprandial glucagon release.
Isoglycaemic intravenous glucose infusion
During isoglycaemic clamp experiments, blood glucose
obtained with intravenous glucose reproduced values with
duodenal glucose, with a mean r2 of 0.88 (0.01) (fig 2A,
table 2). Compared with duodenal glucose perfusion, plasma
levels of insulin and C peptide were markedly diminished
during isoglycaemic clamping (fig 2B, table 2). The resulting
incretin effect (that is, the proportion of insulin secretion
related to intestinal peptides) significantly increased during
the high compared with the low duodenal glucose load,
amounting to 48 (8.2)% and 70 (5.6)% based on plasma
insulin levels and 41 (8.5)% and 51 (9.1)% based on plasma C
peptide levels (fig 2C, D; table 2). Ex(9-39)NH2 significantly
diminished the incretin effect at both duodenal glucose loads
by approximately 50%. This effect was reversible after
cessation of ex(9-39)NH2.
Antroduodenal and pyloric motili ty
Duodenal glucose dose dependently inhibited antral and
duodenal contractility and increased the tonic and phasic
motility of the pylorus (fig 4, table 3). During intravenous
infusion of the GLP-1 receptor antagonist ex(9-39)NH2, a
total of 11 antral phase IIIs occurred in eight of nine
volunteers followed by a short phase I, compared with two
phase IIIs during saline control. Six of these antral phase IIIs
occurred within the 30 minute priming period under ex(9-
39)NH2 during the fasting state. Even with excluding phase
III activities from further analysis, ex(9-39)NH2 significantly
increased the number and motility indices of antral and
duodenal pressure waves during the fasting state and during
both duodenal glucose loads (fig 4, table 3). This stimulating
effect disappeared at cessation of ex(9-39)NH2, suggesting an
inhibitory role of endogenous GLP-1 in this context.
Amplitude and duration of antroduodenal pressure waves
remained unaltered by ex(9-39)NH2 (data not shown).
However, in spite of its stimulating effect, ex(9-39)NH2 did
not prevent inhibition of antroduodenal contractility by
duodenal glucose, which occurred to a similar extent as
during saline.
Stimulation of pyloric tone by duodenal glucose was
inhibited by ex(9-39)NH2 (fig 4, table 3). Although the low
duodenal glucose load also enhanced pyloric tone with
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ex(9-39)NH2 during the first 30 minutes of perfusion, the
GLP-1 antagonist prevented the further increase in tone
during the last 30 minutes of this period and completely
abolished the tonic response to duodenal glucose at 2.5 kcal/
min. Furthermore, the increase in IPPW resembling the
phasic response of the pylorus to duodenal glucose perfusion
was significantly inhibited by ex(9-39)NH2. The typical
pattern of antro-pyloro-duodenal motility seen with ex(9-
39)NH2 infusion is demonstrated in fig 5.
DISCUSSION
This is the first study addressing the effects of endogenous
GLP-1 on release of insulin and pancreatic glucagon and on
motility of the antro-pyloro-duodenal region in humans. The
salient findings are as follows: (i) endogenous GLP-1
significantly enhanced postprandial insulin secretion, sug-
gesting GLP-1 as a true incretin hormone in humans; (ii)
fasting and postprandial GLP-1 suppressed glucagon release;
(iii) GLP-1 mediated stimulation of pyloric motility induced
by intestinal glucose; and (iv) GLP-1 inhibited antro-
duodenal motility during the fasting and postprandial states,
qualifying GLP-1 as an enterogastrone. As GLP-1 controls
mechanisms with an impact on glycaemia, this may be
relevant for type 2 diabetes mellitus for which a deficiency of
bioactive GLP-1 has been suggested.20
It is well known that duodenal glucose dose dependently
increases blood glucose and plasma insulin, suppresses
plasma glucagon, and induces a postprandial motor pattern
with inhibition of antral and stimulation of pyloric motil-
ity.18 21 22 We examined the role of GLP-1 as mediator of these
effects.
Blockade of GLP-1 action by ex(9-39)NH2 raised blood
glucose levels during the fasting state and during both loads
of duodenal glucose. These data support findings that
Table 3 Effects of intravenous exendin(9-39)NH2 on antro-pyloro-duodenal motility during duodenal glucose perfusion at
different rates
IV infusion
Duodenal glucose perfusion rate (60 min each)
1 kcal/min 2.5 kcal/min 2.5 kcal/min (recovery)
Saline iv Ex(9-39) Saline iv Ex(9-39) Saline iv Saline iv
Antral motility
Pressure waves (No/60 min) 13 (3.3) 46 (7.5)* 8.0 (2.6) 16 (3.7)* 24 (6.3) 20 (4.7)
Motility index (mm Hg6s/60 min) 4498 (1622) 9954 (2645)* 364 (144) 1016 (250)* 1549 (461) 2372 (901)
Amplitude (mm Hg) 49 (11) 49 (6.9) 21 (4.0) 25 (6.2) 31 (6.8) 37 (7.7)
Duodenal motility
Pressure waves (No/60 min) 141 (10) 195 (17)* 74 (12) 151 (11)* 131 (20) 143 (17)
Motility index (mmHg6s/60 min) 7118 (1278) 9785 (1376)* 3463 (612) 5711 (804)* 5416 (982) 5776 (877)
Amplitude (mm Hg) 23 (0.8) 24 (1.5) 21 (2.0) 22 (1.7) 22 (1.9) 24 (1.2)
Pyloric motility
IPPW (No/60 min) 26 (5.5) 14 (2.7) 53 (9.5) 24 (6.2)* 47 (9.2) 28 (8.1)*
Pyloric tone (mm Hg) 6.2 (1.0) 5.0 (0.8) 9.8 (1.3) 5.8 (1.1)* 11 (1.5) 6.3 (1.3)*
IPPW, isolated pyloric pressure waves; iv, intravenous.
Mean (SEM) of actual values and of values over basal (pyloric tone) during each 60 minute perfusion period. Values for pressure waves and motility indices
represent the sum of two antral and three duodenal side holes, respectively (n = 9).
Differences were compared using two way repeated measures ANOVA employing individual incremental or decremental values during the respective periods.
*p,0.05 versus saline iv.
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Figure 5 Manometric tracings of the same individual showing the effects of intravenous (iv) infusion of saline (left panel) and exendin(9-39)NH2
300 pmol/kg/min (right panel) during duodenal glucose perfusion at 1 kcal/min. With iv saline, duodenal glucose at 1 kcal/min exerted inhibition of
antral motility, tonic elevation in basal pyloric pressure (arrow), and induced isolated pyloric pressure waves. With iv ex(9-39)NH2, marked antral
contractility was observed leading to two aborally propagated antral phase IIIs. TMPD, transmucosal potential difference.
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endogenous GLP-1 significantly contributes to fasting and
postprandial glucose homeostasis in humans.12 13 During
fasting, plasma insulin remains unchanged under adminis-
tration of the GLP-1 receptor antagonist. On stimulations of
endogenous GLP-1 by duodenal glucose, however, ex(9-
39)NH2 reduced plasma insulin, thereby contributing to
elevated plasma glucose levels. This argues in favour of GLP-1
being a true incretin hormone in humans.
However, the experimental design needs careful considera-
tion when interpreting data in this field. When glucose is
delivered directly and continuously into the bowel, GLP-1
promptly raises plasma insulin. When glucose is swallowed
as a liquid test meal, interference with gastric emptying
needs to be taken into account. To date, only one study in
humans has addressed the effect of ex(9-39)NH2 on
glycaemia after an oral glucose meal. It showed an increase
in incremental postprandial glucose by 35%, which is
comparable with our results, and a paradoxical increase in
plasma insulin.13 We found that blocking the action of GLP-1
resulted in enhancement of postprandial glucagon secretion
and also in stimulation of antral and inhibition of pyloric
motility. Thus after an oral meal, increasing glucagon and
acceleration of gastric emptying rate may result in higher
postprandial glucose levels. Such glucose levels may stimu-
late insulin release, outweighing a putative inhibitory effect
of the GLP-1 antagonist on insulin secretion.
Calculation of the incretin effect from b cell secretory
responses is based on the assumption that after glucose
ingestion, the endocrine pancreas is stimulated by both the
resulting elevation in plasma glucose and the additional
stimulation by gastrointestinal (incretin) factors.23 24
Considering the reduced hepatic insulin extraction after
enteral compared with intravenous glucose, C peptide may be
a better quantitative estimate in determining the b cell
secretory response than plasma insulin.25 26 Regarding plasma
C peptide, the incretin effect (that is, postprandial insulin
secretion triggered by intestinal hormones) rose with
increasing intestinal glucose load, amounting to approxi-
mately 50% at the high dose of duodenal glucose. This
mirrored previous findings by others.27–29 The fraction of the
incretin effect attributable to GLP-1 made up for approxi-
mately 50% with both duodenal glucose loads. It is
remarkable that during infusion of the low duodenal glucose
load, endogenous GLP-1 significantly contributed to the
incretin effect although plasma GLP-1 was not significantly
raised. This points to the high sensitivity of the pancreatic b
cell to GLP-1. GIP probably mediates the residual incretin
effect remaining after blockade of GLP-1. This is at least
suggested by animal studies demonstrating a reduction in
insulin secretion with GIP immunoadsorption, GIP anti-
serum, or GIP receptor antagonists by 20–70%.30–33 It is also in
accordance with the known additive insulinotropic effect of
GIP and GLP-1 in healthy humans.34 35
The order of the intraduodenal infusions at 1 and 2.5
kcal/min was always the same in each experiment and we did
not use a washout period in between. Therefore, we cannot
exclude the fact that the low caloric glucose perfusion may
have influenced parameters obtained at the high caloric
perfusion rate. However, blood glucose and plasma insulin in
the present study increased by nearly identical amounts and
at a similar velocity compared with experiments with
duodenal perfusion of glucose at 1.1 and 2.2 kcal/min
performed on different days.14 Also, the third main outcome
parameter, pyloric tone, promptly and dose dependently
increased in our study, as has been shown previously
including a washout period.18 Therefore, we abstained from
a washout period in order to save ex(9-39)NH2 which is very
expensive. Moreover, the identical design except for the
intravenous background infusions were done on different
days. Thus the potential of an order effect may not explain
the profound effects of ex(9-39)NH2.
Previous in vitro experiments suggested indirect paracrine
suppression of glucagon by somatostatin while revealing that
GLP-1 stimulates somatostatin secretion in isolated rat and
human pancreatic islets and perfused pancreas prepara-
tions.36–38 Hitherto, the effects of endogenous GLP-1 on
postprandial glucagon release in humans were unknown.
The increase in blood glucose with ex(9-39)NH2 during
fasting was accompanied by a significant increase in plasma
glucagon in spite of unchanged insulin, providing suffi-
cient evidence that the pancreatic a cell is under the
tonic inhibitory control of GLP-1 in humans.12 Moreover,
ex(9-39)NH2 completely prevented the decrease in plasma
glucagon occurring with intestinal glucose, suggesting
glucose induced suppression of glucagon being largely
mediated by GLP-1. Clearly, glucagon suppression during
the high duodenal glucose load was abolished by the GLP-1
antagonist while significantly raising plasma GLP-1. This
demonstrates that endogenous GLP-1 not only tonically
suppresses fasting glucagon but further mediates postpran-
dial glucagon inhibition.
Duodenal glucose at 1 kcal/min (1 kcal/ml) did not raise
plasma GLP-1, as previously described.14 However, release of
GLP-1 by duodenal glucose approximating its secretory
threshold may depend on both concentration and flow rate:
the same caloric load at 0.33 kcal/ml and 3 ml/min was
shown to induce a modest increase in GLP-1.39 A higher
duodenal flow rate may overrun the duodenal capacity of
glucose absorption, which is up to 1.4 kcal/min.40
Independent of the ongoing discussion of a neurohumoral
pathway triggering GLP-1 release from the lower intestine in
humans, this may point to the jejunum as a source of GLP-1,
at least under the experimental conditions of direct duodenal
glucose perfusion. During ex(9-39)NH2, plasma GLP-1 was
markedly increased, not during fasting but during duodenal
glucose stimulation. In contrast, ex(9-39)NH2 simultan-
eously infused with synthetic GLP-1 did not augment GLP-
1 plasma levels compared with intravenous GLP-1 alone.12
This argues against an interaction of ex(9-39)NH2 with
metabolism of GLP-1. We therefore suggest autofeedback
inhibition of GLP-1, which is interrupted by the GLP-1
receptor antagonist. This hypothesis is supported by studies
employing the GLP-1 agonist exendin-4, thereby reducing
plasma levels of endogenously released GLP-1.41 How this
putative feedback is regulated in detail remains to be
established.
The third key action of synthetic GLP-1 reducing acute
glycaemia is retardation of gastric emptying. This raises the
question of whether GLP-1 is an enterogastrone (that is, a gut
hormone which mediates feedback inhibition of upper
gastrointestinal motility and/or secretion after intestinal
nutrient exposure). Known motor actions of synthetic GLP-
1 include relaxation of the proximal stomach, inhibition of
antroduodenal contractility, and stimulation of pyloric
motility, with the latter serving as a brake to gastric
emptying.5 6 42 This postprandial pattern of antro-pyloro-
duodenal motility occurs in a similar way after oral meal
intake14 18 43 and was dose dependently mimicked by duoden-
al glucose perfusion.
Even during fasting ex(9-39)NH2 markedly stimulated
antral and duodenal motility, leading to the occurrence of
aborally propagated phase IIIs in most volunteers. This
clearly indicates that fasting antroduodenal motility is
tonically suppressed by GLP-1. Moreover, postprandially
released GLP-1 contributes to inhibition of antroduodenal
motility induced by intestinal carbohydrates. In terms of the
pylorus, ex(9-39)NH2 attenuated stimulation of both its tonic
and phasic motility to low duodenal glucose, and completely
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abolished the further increase in pyloric tone occurring with
the high duodenal glucose load. Thus GLP-1 largely mediates
pyloric stimulation triggered by duodenal carbohydrates. As
the response of antro-pyloro-duodenal motility to intestinal
carbohydrates is significantly modulated by GLP-1, we
suggest the peptide hormone as an enterogastrone in
humans. However, the GLP-1 antagonist was unable to
completely reverse the effects induced by intraduodenal
glucose. Some degree of small intestinal feedback inhibition
may still have been operative. The feedback pathways
mediating antral and pyloric motor response are as yet
poorly understood. In humans, the pyloric motor response to
intraduodenal glucose involves muscarinergic stimulation.21
The impact of intestinal hormones other than GLP-1 released
by carbohydrates is largely unknown. GIP has no effect on
gastric emptying,44 and PYY may inhibit gastric emptying but
its effects on motility are unclear.45 On the other hand, acute
hyperglycaemia is well known to dose dependently slow
gastric emptying, to inhibit antral motility, and to stimulate
pyloric motility.9 As the effects of hyperglycaemia on gastric
emptying and antral motility occur within the normal range
of postprandial glycaemia, the modest elevation in blood
glucose during duodenal glucose may have superimposed the
motility effects of the GLP-1 antagonist.
The precise mechanism for GLP-1 stimulating pyloric
and inhibiting antral motility is not entirely clear. Animal
studies indicated no direct effect of GLP-1 on gastric smooth
muscle cells.46 47 Multiple findings support the notion that
suppression of vagal neural input is involved in the inhibition
of gastric motor functions by exogenous GLP-1.3 4 48 GLP-1
may interact with vagal afferent nerves49 or may affect
specific GLP-1 binding sites in the area postrema accessible to
GLP-1 from the systemic circulation.50 51 However, as the
pylorus is stimulated by vagal cholinergic activity, its
stimulation by GLP-1 may not be mediated by cholinergic
inhibition. Further studies are required to elucidate the
mechanisms which mediate gastric motor effects induced by
GLP-1.
In conclusion, we have demonstrated that endogenous
GLP-1 plays an important role in the fasting and postprandial
regulation of endocrine pancreatic secretion and of antro-
pyloro-duodenal motility in humans. As an incretin hor-
mone, GLP-1 glucose dependently stimulates insulin secre-
tion. It tonically suppresses glucagon release and lowers
postprandial glucagon excursions. As enterogastrone, it
inhibits antral and stimulates pyloric motility, both of which
may contribute to inhibition of gastric emptying.
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